Last updated: September 8, 2026
Sulbactam-durlobactam, marketed in the United States as Xacduro, is a hospital anti-infective for adults with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex. The product combines the established beta-lactamase inhibitor sulbactam sodium with durlobactam sodium, a newer diazabicyclooctane beta-lactamase inhibitor.
The commercial opportunity is strategically important but economically narrow. Xacduro addresses carbapenem-resistant Acinetobacter, a high-mortality hospital infection with limited treatment options. Its revenue ceiling is constrained by the small number of eligible infections, hospital stewardship, intravenous administration, and competition from cefiderocol, polymyxins, tetracycline-class agents, and other rescue therapies.
What is durlobactam sodium and how does Xacduro work?
Durlobactam sodium is a beta-lactamase inhibitor designed to inhibit class A, class C, and certain class D beta-lactamases produced by Acinetobacter species. It is administered with sulbactam sodium.
Sulbactam has intrinsic antibacterial activity against Acinetobacter, but many resistant strains produce beta-lactamases that degrade sulbactam. Durlobactam protects sulbactam from those enzymes and restores its activity against susceptible organisms.
| Product attribute |
Xacduro profile |
| Active ingredients |
Sulbactam sodium and durlobactam sodium |
| Dosage form |
Intravenous infusion |
| Standard adult dose |
Sulbactam 1 g plus durlobactam 1 g every six hours |
| Approved indication |
Hospital-acquired and ventilator-associated bacterial pneumonia |
| Target pathogen |
Susceptible Acinetobacter baumannii-calcoaceticus complex |
| U.S. approval |
May 23, 2023 |
| Original developer |
Entasis Therapeutics |
| Current commercial owner |
Innoviva |
| Regulatory category |
Qualified Infectious Disease Product and priority review product |
The FDA approved Xacduro based primarily on the ATTACK trial, which compared sulbactam-durlobactam with colistin in patients with infections caused by Acinetobacter baumannii-calcoaceticus complex. Xacduro demonstrated noninferior 28-day all-cause mortality and lower nephrotoxicity than colistin in the relevant trial population.[1]
Who owns and markets durlobactam sodium?
Innoviva owns the commercial rights through its acquisition of Entasis Therapeutics. Innoviva completed the acquisition in 2023 after previously supporting Entasis through financing and collaboration arrangements.[2]
The ownership structure gives Innoviva direct control over U.S. commercialization, pricing, hospital contracting, and lifecycle strategy. It also leaves Innoviva exposed to the limited scale of the Acinetobacter market because Xacduro does not have a broad community-acquired or general hospital pneumonia indication.
The principal commercial stakeholders are:
| Company |
Role |
| Innoviva |
Parent company and commercial owner |
| Entasis Therapeutics |
Original developer of durlobactam and sulbactam-durlobactam |
| FDA |
U.S. regulatory authority |
| Hospital systems |
Primary purchasing and formulary customers |
| Infectious-disease specialists |
Main prescribing decision-makers |
| Clinical microbiology laboratories |
Important source of susceptibility and pathogen data |
How large is the market for sulbactam-durlobactam?
The addressable market is concentrated in multidrug-resistant Acinetobacter infections, particularly in intensive-care settings. It is materially smaller than the markets for broad-spectrum hospital antibiotics.
Demand is shaped by four factors:
- The incidence of carbapenem-resistant Acinetobacter.
- The proportion of patients with confirmed or suspected susceptible organisms.
- Hospital adoption and formulary placement.
- Reimbursement relative to acquisition cost and administration expense.
The World Health Organization classifies carbapenem-resistant Acinetobacter baumannii as a critical-priority pathogen. This designation supports hospital demand and public-sector interest, but it does not create a large recurring prescription market.[3]
Xacduro is most likely to be used in hospitals with:
- High rates of carbapenem-resistant Acinetobacter.
- Intensive-care and ventilator-associated pneumonia programs.
- Infectious-disease consultation services.
- Rapid susceptibility testing.
- Established antimicrobial stewardship infrastructure.
Use is less likely in hospitals where Acinetobacter infections are uncommon or where treatment decisions are made empirically without rapid pathogen identification.
What is the financial trajectory for Xacduro?
Xacduro entered the U.S. market in 2023, so its financial trajectory begins with a launch and formulary-conversion phase rather than a mature-product cycle. Innoviva reports product revenue at the corporate level, but public disclosures do not always provide a complete, consistently separated revenue series for Xacduro by quarter.
The commercial trajectory has four phases:
| Phase |
Timing |
Financial characteristics |
| Launch |
2023 |
Initial stocking, access contracts, medical education, limited revenue base |
| Formulary expansion |
2024-2026 |
Growth depends on hospital protocols and microbiology-driven prescribing |
| Specialty anti-infective maturity |
2026 onward |
Revenue tied to resistant-infection incidence and repeat institutional use |
| Post-exclusivity pressure |
Early-to-mid 2030s or later |
Generic entry risk depends on patents, regulatory exclusivity, and product complexity |
The product has a favorable value proposition against colistin because the clinical program showed lower nephrotoxicity. Avoided renal injury, reduced intensive-care resource use, and improved treatment confidence can support hospital adoption even if the acquisition price is higher than older generic antibiotics.
Revenue expansion is unlikely to come from a large increase in patient volume. It is more likely to come from:
- Greater use as empiric therapy in high-risk intensive-care patients.
- Broader hospital formulary placement.
- Higher use in regions with rising carbapenem-resistant Acinetobacter prevalence.
- Improved diagnostic turnaround.
- Contracting with government hospitals and integrated delivery networks.
- International approvals and distributor partnerships.
How does Xacduro compare with competing treatments?
Xacduro competes against both branded and generic therapies. Its principal commercial advantage is the combination of targeted Acinetobacter activity and a more favorable renal safety profile than colistin.
| Therapy |
Commercial position |
Main advantage |
Main limitation |
| Xacduro |
Branded combination product |
Targeted activity and lower nephrotoxicity than colistin in clinical development |
Narrow indication and IV administration |
| Colistin |
Low-cost generic rescue therapy |
Familiarity and low acquisition cost |
Nephrotoxicity and difficult dosing |
| Cefiderocol |
Branded siderophore cephalosporin |
Broad activity against certain resistant gram-negative organisms |
Variable clinical positioning and high cost |
| High-dose ampicillin-sulbactam |
Generic alternative |
Low cost and established use |
Resistance and tolerability concerns |
| Minocycline or tigecycline |
Generic or branded options |
Activity in selected resistant infections |
Pharmacokinetic and tolerability limitations |
| Polymyxin-based regimens |
Generic rescue therapy |
Availability |
Toxicity and uncertain comparative utility |
Xacduro is not a broad substitute for cefiderocol or meropenem-vaborbactam. The relevant competitive question is whether a hospital views the product as a preferred targeted option for Acinetobacter rather than as a general reserve antibiotic.
What FDA exclusivity protects Xacduro?
FDA approval occurred on May 23, 2023. Xacduro received Qualified Infectious Disease Product status, which provides a five-year extension to certain applicable exclusivity periods under the Generating Antibiotic Incentives Now framework.[4]
Durlobactam was a new active ingredient at approval, while sulbactam was an established beta-lactamase inhibitor. The practical exclusivity position therefore depends on the interaction of new chemical entity exclusivity, QIDP extension, orphan-drug status if applicable, and listed patents.
The relevant regulatory milestones are:
| Milestone |
Date or status |
| FDA approval |
May 23, 2023 |
| QIDP designation |
Granted before approval |
| New chemical entity analysis |
Applies primarily to durlobactam |
| Regulatory exclusivity end date |
Must be confirmed through FDA exclusivity records |
| Patent expiry |
Depends on issued patents, patent-term adjustment, and any extension |
| Generic approval pathway |
Abbreviated New Drug Application, subject to applicable listed patents |
Regulatory exclusivity should not be confused with patent life. A generic applicant may file an ANDA before patent expiration and submit a Paragraph IV certification challenging listed patents.
What patents protect durlobactam sodium and Xacduro?
The patent estate is expected to cover several layers:
- Durlobactam composition of matter.
- Pharmaceutical salts, including durlobactam sodium.
- Sulbactam-durlobactam combinations.
- Injectable formulations.
- Dosing regimens.
- Treatment of Acinetobacter infections.
- Manufacturing and purification processes.
The strongest protection is generally the composition-of-matter patent covering durlobactam or its core chemical structure. Combination and method-of-use patents can extend commercial protection but are more vulnerable to validity and infringement challenges.
The FDA Orange Book should be used to determine the patents listed against Xacduro’s NDA 216974 and to identify expiration dates, pediatric extensions, and any patent-term adjustment.[5] Publicly available information does not establish a complete, verified patent-expiration schedule for every jurisdiction and claim category.
When could generic entry occur?
A generic challenger would need to address both regulatory and technical barriers. Xacduro is an injectable fixed-dose combination, which is more complex than a conventional oral tablet. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA standard for the combination product.
Potential generic entry scenarios include:
| Scenario |
Commercial effect |
| No Paragraph IV challenge |
Entry generally waits for patent or exclusivity expiry |
| Successful Paragraph IV challenge |
Earlier entry is possible, subject to litigation and regulatory timing |
| First-filer settlement |
Entry date depends on settlement terms and court outcome |
| At-risk launch |
Could trigger damages exposure and immediate patent litigation |
| Post-expiry multi-source entry |
Likely rapid price erosion in hospital purchasing |
A generic entrant would probably compete on acquisition price rather than clinical differentiation. Hospitals may retain Xacduro for protocols, physician familiarity, and supply reliability, but branded price premiums would become difficult to sustain after multiple generic approvals.
What litigation and settlement risks affect Xacduro?
The major foreseeable litigation risk is Paragraph IV patent litigation initiated after an ANDA filing. A challenge could target composition, formulation, combination, method-of-use, or process claims.
No confirmed public settlement structure should be assumed without a filed court record or company disclosure. For commercial forecasting, the principal variables are:
- The number of Orange Book-listed patents.
- The earliest expiration of composition claims.
- Whether the listed patents qualify for statutory litigation stays.
- The presence of pediatric exclusivity.
- The timing of the first ANDA.
- Any authorized-generic strategy by Innoviva or a licensee.
How strong is the durlobactam patent estate?
The estate is commercially strongest if it includes a valid composition-of-matter patent with a late expiration date and claims that cover the marketed durlobactam sodium form. Combination and formulation patents provide secondary protection but are less durable if a generic can design around them.
Technical barriers remain meaningful because the product requires sterile intravenous manufacturing, accurate active-ingredient ratios, stability control, and reliable supply of both components. These barriers can delay entry, but they do not replace enforceable patent protection.
What licensing deals could expand Xacduro revenue?
International licensing and regional commercialization partnerships are the clearest routes to revenue expansion outside the United States. Potential partners would value:
- Existing regulatory approval.
- A differentiated hospital anti-infective profile.
- Access to markets with high carbapenem-resistant Acinetobacter prevalence.
- Government procurement capability.
- Established infectious-disease sales infrastructure.
The economics of a licensing deal would likely include upfront payments, milestone payments, regional royalties, and supply commitments. Because the market is specialized, Innoviva may prefer a small number of regional partners rather than a large global sales organization.
What generic and commercial risks face durlobactam sodium?
The principal risks are:
- Low infection volume relative to broad-spectrum antibiotics.
- Hospital budget pressure.
- Delayed diagnosis of Acinetobacter infections.
- Competition from lower-cost sulbactam-based regimens.
- Physician preference for established rescue treatments.
- Generic or authorized-generic entry after patent challenges.
- Manufacturing interruptions involving either active ingredient.
- Limited use outside the approved pneumonia indication.
- International reimbursement constraints.
The main upside is increased resistance prevalence. If carbapenem-resistant Acinetobacter becomes more common in intensive-care units, Xacduro can gain protocol status as a preferred therapy. Its commercial performance depends less on general antibiotic demand than on resistance epidemiology and institutional treatment pathways.
Key Takeaways
- Xacduro is the U.S. branded combination of durlobactam sodium and sulbactam sodium.
- FDA approval occurred on May 23, 2023, for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter.
- The product’s value proposition is targeted activity with lower nephrotoxicity than colistin in the ATTACK clinical program.
- The addressable market is specialized and hospital-based, limiting absolute revenue potential.
- Innoviva’s growth depends on formulary adoption, diagnostic testing, international partnerships, and rising carbapenem-resistant Acinetobacter prevalence.
- QIDP status extends applicable regulatory exclusivity, but patent expiration and Orange Book listings determine the practical timing of generic risk.
- No biosimilar pathway applies because Xacduro is a small-molecule antibacterial combination.
- The strongest patent protection would come from valid durlobactam composition claims, supported by combination, formulation, method-of-use, and manufacturing patents.
FAQs
Is durlobactam sodium the same as sulbactam sodium?
No. Durlobactam is a beta-lactamase inhibitor that protects sulbactam. Sulbactam has intrinsic antibacterial activity against Acinetobacter, while durlobactam improves the durability of that activity against resistant strains.
Is Xacduro used for urinary tract infections?
Xacduro’s U.S. approval is for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter. Use in other infections may be off-label.
Does Xacduro have a biosimilar competitor?
No. Xacduro is a small-molecule antibacterial combination, so competition would come through generic drug applications rather than biosimilar applications.
What is the most important commercial competitor to Xacduro?
Colistin is the key economic comparator because it is inexpensive and familiar but substantially more nephrotoxic. Cefiderocol is the principal branded comparator in resistant gram-negative hospital infections.
Can a generic company challenge Xacduro before patent expiration?
Yes. An ANDA applicant can file a Paragraph IV certification against listed patents. Innoviva or the patent holder could then bring patent litigation, potentially triggering a statutory stay of FDA approval.
References
-
U.S. Food and Drug Administration. (2023). FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex. https://www.fda.gov
-
Innoviva, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov
-
World Health Organization. (2024). Bacterial priority pathogens list, 2024. https://www.who.int
-
U.S. Food and Drug Administration. (2023). Xacduro prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
